目的 探究血清CXC趋化因子配体1（CXCL1）、正性调节区锌指蛋白5（PRDM5）与进展期胃癌淋巴结转移、预后的关系。 方法 选取2020年6月至2023年3月医院确诊的进展期胃癌患者203例，依据有无淋巴结转移将其分为淋巴结转移组（n = 90）与无淋巴结转移组（n = 113），绘制ROC曲线分析CXCL1、PRDM5在进展期胃癌淋巴结转移中的诊断价值，logistic回归分析进展期胃癌患者淋巴结转移的危险因素。随访2年，绘制Kaplan-Meier曲线比较不同CXCL1、PRDM5水平进展期胃癌淋巴结转移患者的预后情况。 结果 淋巴结转移组CXCL1水平高于无淋巴结转移组，PRDM5水平低于无淋巴结转移组（P < 0.05）。CXCL1、PRDM5诊断进展期胃癌淋巴结转移的AUC分别为0.755、0.844，联合诊断AUC为0.898。肿瘤大小、分化程度、血清CEA、血清CA19-9、CXCL1、PRDM5均为进展期胃癌淋巴结转移的危险因素（P < 0.05）。CXCL1 > 96.13 pg/mL患者生存时间为（15.13 ± 0.85）个月，CXCL1 ≤ 96.13 pg/mL患者生存时间为（19.06 ± 0.66）个月，CXCL1 ≤ 96.13 pg/mL患者生存时间长于CXCL1 > 96.13 pg/mL患者（P < 0.05）。PRDM5 > 100.85 pg/mL患者生存时间为（18.62 ± 0.69）个月，PRDM5 ≤ 100.85 pg/mL患者生存时间为（14.60 ± 0.78）个月，PRDM5 > 100.85 pg/mL患者生存时间长于PRDM5 ≤ 100.85 pg/mL患者（P < 0.05）。 结论 CXCL1水平异常升高、PRDM5水平异常降低与进展期胃癌患者淋巴结转移有关，二者联合检测在进展期胃癌患者淋巴结转移以及预后评估中具有较高的应用价值。

Objective To investigate the relationship between serum CXC chemokine ligand 1 （CXCL1） and positive regulatory zone zinc finger protein 5 （PRDM5） levels and lymph node metastasis of progressive gastric cancer and to analyze their predictive value for patients' prognosis. Methods 203 patients with progressive gastric cancer diagnosed in our hospital from June 2020 to March 2023 were selected and divided into the lymph node metastasis group （n = 90） and the no-lymph node metastasis group （n = 113） based on the presence or absence of lymph node metastasis， and the differences in the general information of the two groups were analyzed and compared， and the diagnostic value of CXCL1 and PRDM5 in lymph node metastasis of progressive gastric cancer was analyzed by plotting the ROC curve. Logistic regression was used to analyze the risk factors of lymph node metastasis in patients with progressive gastric cancer. Follow up for 2 years， draw Kapan Meier curves to compare the prognosis of patients with advanced gastric cancer lymph node metastasis at different levels of CXCL1 and PRDM5. Results The CXCL1 level in the lymph node metastasis group was higher than that in the no-lymph node metastasis group， and its PRDM5 level was lower than that in the no-lymph node metastasis group （P < 0.05）.The AUCs for diagnosing lymph node metastasis of progressed gastric cancer were 0.755 and 0.844 for CXCL1 and PRDM5， respectively， and the AUC for the combination of the two was 0.898 （95% CI 0.848 ~ 0.936）. The sensitivity and specificity were 88.89% and 77.88%， respectively （P < 0.05）.Tumor size， differentation degree， serum CEA， serum CA19-9， CXCL1， and PRDM5 levels were all risk factors for lymph node metastasis in patients with progressive gastric cancer （P < 0.05）. The survival time of patients with CXCL1 > 96.13 pg/mL is （15.13 ± 0.85） months， while the survival time of patients with CXCL1 ≤ 96.13 pg/mL is （19.06 ± 0.66） months. The survival time of patients with CXCL1 ≤ 96.13 pg/mL is longer than that of patients with CXCL1>96.13 pg/mL （P<0.05）. The survival time of patients with PRDM>100.85 pg/mL is （18.62 ± 0.69） months， while the survival time of patients with PRDM ≤ 100.85 pg/mL is （14.60 ± 0.78） months. The survival time of patients with PRDM>100.85 pg/mL is longer than that of patients with PRDM ≤ 100.85 pg/mL （P<0.05）. Conclusion The abnormal expression of CXCL1 and PRDM5 is related to lymph node metastasis in patients with progressive gastric cancer， and the combined detection of the two is of high value in the assessment of lymph node metastasis and prognosis in patients with progressive gastric cancer.